CT-95 in Advanced Cancers Associated With Mesothelin Expression

Summary

This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Mesothelin-Expressing Tumors
• Epithelial Ovarian Cancer
• Malignant Pleural Mesothelioma, Advanced
• Malignant Peritoneal Mesothelioma, Advanced
• Pancreatic Adenocarcinoma Advanced or Metastatic
• Lung Adenocarcinoma Metastatic
• Cholangiocarcinoma Advanced
• Cholangiocarcinoma Non-resectable
• Mesothelin-expressing Advanced Cancers
• Mesothelin-positive Advanced Malignant Solid Tumors
• Colorectal Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Context Therapeutics Inc.

Last updated on ClinicalTrials.gov

June 12, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites